🇺🇸 FDA
Pipeline program

Solriamfetol

IRB00295382

Phase 2 small_molecule active

Quick answer

Solriamfetol for Multiple Sclerosis is a Phase 2 program (small_molecule) at Axsome Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Axsome Therapeutics
Indication
Multiple Sclerosis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials